Added to YB: 2025-01-07
Pitch date: 2025-01-07
LQDA [bullish]
Liquidia Corporation
+445.81%
current return
Author Info
No bio for this author
Company Info
Liquidia Corporation, a biopharmaceutical company, develops, manufactures, and commercializes various products for rare cardiopulmonary diseases in the United States.
Market Cap
$6.1B
Pitch Price
$12.40
Price Target
N/A
Dividend
N/A
EV/EBITDA
35.32
P/E
46.46
EV/Sales
13.40
Sector
Pharmaceuticals
Category
special_situation
Yutrepia's Launch: A Catalyst for Liquidia (LQDA)
LQDA: Liquidia has developed a dry-powder inhaled treprostinil treatment for PAH and PH-ILD, with a May 2025 launch assumed after United Therapeutics’ FDA-granted NCI exclusivity expires. A pending lawsuit could permit earlier sales following the Supreme Court’s rejection of United Therapeutics’ last appeal. Shares could at least double if the launch works out, but the timing remains exposed to the FDA dispute and court ruling.
Read full article (1 min)